Breakthroughs in Autoimmune Disease Drug Discovery: Cloud-Clone’s End-to-End Toolkit from Molecules to Animal Models

Overcoming Heterogeneity-Driven Bottlenecks to Accelerate Novel Therapeutic Development

HUSTON, TX, UNITED STATES, November 3, 2026 /EINPresswire.com/ -- Systemic autoimmune diseases (SAIDs) represent a major unmet medical challenge worldwide. Characterised by dysregulated immune tolerance where the immune system erroneously attacks multiple organs and tissues, conditions including systemic lupus erythematosus and rheumatoid arthritis feature relapsing-remitting disease courses and high disability rates. Complex interplay of genetics, environmental triggers and immune dysregulation complicates mechanistic deciphering and curative treatment development. While novel targets and biomarkers keep emerging in autoimmune-disease research, profound disease heterogeneity remains a core bottleneck for basic mechanistic studies, target validation and innovative targeted-drug development. High-quality recombinant proteins, specific antibodies, standardised animal models and primary-cell models serve as four cornerstone research tools to advance SAID mechanism exploration, target screening and pharmacodynamic evaluation. Cloud-Clone has built an integrated portfolio of molecular reagents, primary-cell models and in-vivo disease models to deliver full-chain, standardised technical support for global researchers investigating SAID fundamental biology, mechanistic dissection and innovative drug translation.

Molecular Reagent Portfolio: Recombinant Proteins and Target-Specific Antibodies Underpin Foundational Research
For systemic autoimmune-disease studies, recombinant proteins and target-specific antibodies are essential tools for molecular-mechanism investigation, biomarker detection, target validation and signalling-pathway analysis. The specificity, sensitivity and stability of these reagents directly govern the accuracy and reproducibility of experimental data.
Focusing on mainstream SAID research targets and core signalling cascades, Cloud-Clone has developed research reagents targeting anti-SSA/Ro, anti-SSB/La antibodies, inflammatory cytokines and cell-specific markers. Validated across Western Blot (WB), Immunohistochemistry (IHC) and ELISA platforms, these reagents deliver high specificity, high titre and low non-specific binding. They support diverse research workflows including autoantibody screening, inflammatory-pathway activation profiling, immune-cell phenotyping and key-protein expression measurement, furnishing robust molecular-reagent support for downstream cellular functional assays, animal-model establishment and in-vivo pharmacodynamic assessment.

Figure 1. Validation data of anti-SSA/Ro antibody

Standardised Animal Models: Recapitulating Clinical Pathological Phenotypes to Enable In-Vivo Pharmacodynamic Assessment
Animal disease models act as a critical bridge linking in-vitro experiments and clinical translation. They faithfully recapitulate multi-system immune-injury pathological hallmarks observed in human patients, and constitute vital assay systems for autoimmune-disease mechanistic dissection, candidate-drug screening, as well as in-vivo efficacy and safety profiling.
Cloud-Clone maintains a comprehensive SAID animal-model library covering two major categories: induced models and spontaneous genetic models. The portfolio spans prevalent research indications including rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and type 1 diabetes, catering for diverse research workflows and new-drug development requirements.

Rheumatoid Arthritis Models (CIA / AIA)
For rheumatoid arthritis (RA) research, Cloud-Clone provides collagen-induced arthritis (CIA) and adjuvant-induced arthritis (AIA) models. The CIA model reliably induces joint synovitis, excessive synovial proliferation, cartilage and bone destruction, accompanied by hallmark clinical manifestations such as paw swelling and joint deformity. Its pathological features closely resemble human rheumatoid arthritis. With controllable modelling timelines and scalable batch preparation, CIA is widely deployed for high-throughput in-vivo efficacy screening of anti-inflammatory agents and novel antibody therapeutics. The AIA model features a short modelling cycle and stable phenotypes, suited for rapid evaluation of anti-inflammatory intervention effects.

Figure 2. Adjuvant-induced arthritis (AIA) model; prominent paw swelling is observed in the model group.

MRL/lpr Spontaneous Model for Systemic Lupus Erythematosus
For systemic lupus erythematosus research, Cloud-Clone offers the classic MRL/lpr spontaneous lupus mouse model. Mice of this strain carry the lpr gene mutation leading to impaired Fas-protein function and defective lymphocyte apoptosis. They spontaneously generate lupus-signature autoantibodies including anti-dsDNA and antinuclear antibodies, and progressively develop glomerulonephritis, vasculitis, splenomegaly, lymphadenopathy and multi-organ immune-complex deposition. Disease progression closely mirrors human systemic lupus erythematosus, rendering this model suitable for dissecting disrupted immune-tolerance mechanisms and conducting long-term pharmacodynamic evaluation.

Figure 3. H&E-stained kidney tissue sections from the systemic lupus erythematosus model.

STZ-Induced Animal Model for Type 1 Diabetes
Type 1 diabetes mellitus (T1DM) is an organ-specific autoimmune disorder mediated by T-cell-driven destruction of pancreatic β-cells. Owing to insidious disease onset in human patients and difficulties accessing early-stage pancreatic specimens, animal models represent indispensable research tools. Cloud-Clone’s STZ-induced T1DM model features straightforward operation, manageable costs and rapid disease onset with stable hyperglycaemic phenotypes. It is a standardised workhorse for research into insulin-replacement therapies, blood-glucose-regulatory mechanisms and novel anti-diabetic agents.

Figure 4. H&E-stained heart, lung and kidney tissue sections from the type 1 diabetes model.

Diverse Autoimmune-Disease Models Tailored for Distinct Research Scenarios
Beyond core mainstream models, Cloud-Clone delivers custom-built animal models for psoriasis and experimental autoimmune encephalomyelitis (EAE). Induced models feature well-established workflows, high batch-to-batch consistency and cost-effectiveness, ideal for high-throughput preliminary drug screening. Spontaneous genetic models exhibit high clinical relevance and complete multi-organ-injury phenotypes, and are better-suited for in-depth mechanistic research and long-term pharmacodynamic validation.
All animal-model services include standardised modelling workflows. Deliverables encompass full sets of experimental datasets including body-weight monitoring, clinical-score documentation, serum autoantibody measurement, cytokine profiling and H&E histopathology, enabling systematic assessment of drug efficacy, safety and mechanism of action.

Versatile Primary-Cell Models: Dissecting Immune-Inflammation and Tissue-Injury Mechanisms In-Vitro
In-vitro cellular models form foundational assay platforms for molecular-mechanism mining, signalling-pathway validation and high-throughput preliminary drug screening, enabling focused investigation of cellular-level immune-inflammatory responses and tissue-damage mechanisms. Cloud-Clone maintains a library of more than 540 primary-cell products covering human, mouse, rat, rabbit, dog and other common experimental species. Compared with immortalised cell lines, primary cells largely retain native in-vivo physiological properties, better recapitulating authentic pathological contexts.
Cloud-Clone supplies application-specific primary-cell tools aligned with target-organ injury signatures of different SAIDs. For systemic lupus erythematosus research, epidermal keratinocytes and dermal fibroblasts support investigations into pathological mechanisms such as cutaneous photosensitivity and fibrosis. For rheumatoid-arthritis studies, primary synoviocytes and chondrocytes faithfully recapitulate core pathological events including aberrant synovial hyperproliferation, pro-inflammatory-cytokine secretion and cartilage degradation.

Figure 5. Primary-cell products for SAID-related research.
Additional primary-cell resources including vascular endothelial cells, microglia and macrophages are also available to support cellular-level studies on immune modulation, inflammatory activation and tissue-injury repair in SAID research.

Integrated End-to-End Empowerment: Advancing Autoimmune-Disease Research and New-Drug Translation
Disease heterogeneity constitutes the key barrier impeding fundamental-research breakthroughs and clinical translation of autoimmune-disease therapeutics. Cloud-Clone integrates high-quality molecular reagents, standardised animal models and functionally competent primary-cell in-vitro models, establishing a complete SAID research workflow spanning molecular validation, cellular-mechanism interrogation and in-vivo pharmacodynamic assessment.
Leveraging multi-modal product synergy, Cloud-Clone empowers global researchers to efficiently uncover novel disease biomarkers and identify innovative therapeutic targets, mitigating research obstacles driven by autoimmune-disease heterogeneity. The platform helps shorten new-drug development timelines and minimise experimental variability, delivering robust research tools to drive innovation in basic autoimmune-disease science and accelerate the clinical translation of novel therapeutics.

As global autoimmune-disease research keeps advancing, reliable, standardised research reagents and model systems are critical to bridge laboratory discoveries and clinical applications. Cloud-Clone will continue optimising its full-chain research-tool portfolio, supporting worldwide research communities to tackle unmet medical needs brought by complex systemic autoimmune diseases.

About Cloud-Clone Corp.
Cloud-Clone Corp. is dedicated to the development and production of high-quality immunoassay reagents and detection solutions. With a focus on antibody engineering, multiplex assay development, and cross-platform compatibility, the company provides research tools designed to support precision medicine and advanced biomedical investigation globally. Our core products and services include the research and development of proteins, antibodies, ELISA kits, primary cells, and multiplex cytokine assay kits, as well as professional CRO services to fully meet the diverse needs of biomedical research and related fields.
For more information about Cloud-Clone Corp, visit www.cloud-clone.com.

CLOUD-CLONE CORP.(CCC)
Tel: 001-832-538-0970, 0086-27-8425-9552
Email: mail@cloud-clone.com, sales@cloud-clone.us

Visit us on social media:
LinkedIn: https://www.linkedin.com/company/cloud-clone-corp/
Instagram: https://www.instagram.com/cloudclonecorp2023/
TickTok: https://www.tiktok.com/@cloudclonecorp2026

SuKi Duan
CLOUD-CLONE CORP.WUHAN
Visit us on social media:
LinkedIn
Instagram
TikTok
X